On GLP-1 medications, you're fighting three dehydration mechanisms simultaneously: Reduced thirst signaling (central appetite suppression affects thirst centers) Reduced fluid intake with meals (nausea makes drinking unpleasant) Ongoing fluid loss from glycogen metabolism during weight loss The result is chronic mild dehydration in a substantial portion of patients during titration
Users who benefit most from this component are those looking for structure and accountability rather than personalized nutrition planning
In the cerebral cortex, GLP-1R is expressed on neurons and glia [42], while in the spinal cord, GLP-1R is coexpressed only with microglia [20]
Fatty liver disease is when fat builds up in your liver
The efficacy of GLP-1 RAs, semaglutide and liraglutide, for the management of weight regain after bariatric surgery was documented by Jensen et al
Currently OCA is being evaluated in a large phase III, randomised, placebo-controlled trial termed REGENERATE